MXCT on Nasdaq

MaxCyte (United States)

American commercial physical and biological research services company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with OmniAb, Inc., FOXO TECHNOLOGIES INC. or bioAffinity Technologies, Inc., or pick any stock.

  • TickerMXCT on Nasdaq1
  • IndustryServices-Commercial Physical & Biological Research1
  • HeadquartersRockville1
  • Websitemaxcyte.com
  • Legal formDelaware corporation1
  • Listed onNasdaq (MXCT), London Stock Exchange (MXCT), Nasdaq (MXCT)1
  • Incorporated inDE4
  • Business address9713 Key West Avenue,, Suite 400, Rockville, Md 208504
  • Filer category, Emerging growth company4
  • LEI54930053YHXULRFCU9913
  • StatusActive3
  • LEI statusLapsed (not renewed)3
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States3
  • Registered withDivision of Corporations, Department of State, 29279453

See how the biggest companies compare on our leaderboards

We are a leading commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics including cell and gene therapies and to support innovative cell-based research and development. Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation ® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

127.9%Gross margin6
-247.6%Operating margin6
-213.0%Net margin6
-5.7%Revenue growth, 20256
-26.0%Return on equity6
-$36.2MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 89% of the revenue MaxCyte (United States) broke down this way in fiscal 2025.

  1. Product$18.7M689%down 11% from 2024
  2. Assay and Other Service Revenue$2.0M69%
  3. License$300.0K61%down 98% from 2024
Products and services by year
Products and services20242025
Product$21.1M$18.7M
Assay and Other Service Revenue$2.0M
License$16.4M$300.0K

Regions

United States brought in 64% of the revenue MaxCyte (United States) broke down this way in fiscal 2025.

  1. United States$21.1M664%down 18% from 2024
  2. Outside the United States$11.9M636%down 7% from 2024
Regions by year
Regions20242025
United States$25.8M$21.1M
Outside the United States$12.9M$11.9M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue23¢$6.2M
  • Research and development77¢$20.8M

Out of $21.0M in revenue.6 The company lost money this year.

Financial statements

Revenue789106$21.0M in 2025+58% since 2019
0$10.0M$20.0M$30.0M2019: $13.3M$13.3M20192020: $15.5M$15.5M2020+17%2021: $21.6M$21.6M2021+40%2022: $28.7M$28.7M2022+33%2023: $19.5M$19.5M2023−32%2024: $22.2M$22.2M2024+14%2025: $21.0M$21.0M2025−6%
Gross profit789106$26.8M in 2025+40% since 2019
0$10.0M$20.0M$30.0M$40.0M2019: $19.1M$19.1M20192020: $23.4M$23.4M2020+22%2021: $30.2M$30.2M2021+29%2022: $39.2M$39.2M2022+29%2023: $36.5M$36.5M2023−7%2024: $31.5M$31.5M2024−14%2025: $26.8M$26.8M2025−15%
Operating income789106-$51.9M in 2025+318% since 2019
-$60.0M-$40.0M-$20.0M02019: -$12.4M-$12.4M20192020: -$11.1M-$11.1M2020−11%2021: -$18.2M-$18.2M2021+65%2022: -$27.4M-$27.4M2022+50%2023: -$48.3M-$48.3M2023+77%2024: -$51.2M-$51.2M2024+6%2025: -$51.9M-$51.9M2025+1%
Net income789106-$44.6M in 2025+246% since 2019
-$60.0M-$40.0M-$20.0M02019: -$12.9M-$12.9M20192020: -$11.8M-$11.8M2020−8%2021: -$19.1M-$19.1M2021+61%2022: -$23.6M-$23.6M2022+24%2023: -$37.9M-$37.9M2023+61%2024: -$41.1M-$41.1M2024+8%2025: -$44.6M-$44.6M2025+9%

Every line of the income statement as filed: the last 2 fiscal years, latest first.6

Period ending2025-12-312024-12-31
Revenue$33.0M$38.6M
Cost of goods sold$6.2M$7.1M
Gross profit$26.8M$31.5M
Research and development$20.8M$22.2M
Sales and marketing$18.9M$26.7M
General and administrative$28.1M$29.7M
Restructuring expense$3.1M
Goodwill impairment$3.6M
Depreciation and amortization$4.2M$4.1M
Total operating expenses$78.7M$82.7M
Operating loss-$51.9M-$51.2M
Interest income$7.3M$10.1M
Total other income$7.3M$10.1M
Loss before income taxes-$44.6M-$41.1M
Net loss-$44.6M-$41.1M
Basic net loss per share-$0.42-$0.39
Diluted net loss per share-$0.42-$0.39
Weighted-average shares outstanding, basic106.4M shares104.8M shares
Weighted-average shares outstanding, diluted106.4M shares104.8M shares

Compare MaxCyte (United States) with another company

Leadership

Who has led MaxCyte (United States), and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Douglas Doerfler2021–2023
  2. Maher Masoud2024–now

President

  1. Douglas Doerfler2021–2023
  2. Maher Masoud2024–now

Chief financial officer

  1. Ron Holtz2023
  2. Douglas J. Swirsky2023–2026
  3. Parmeet Ahuja2026–now
2025
Board members and other officers (16)

Former names

  • MAXCYTE INCApr 14, 2004 to Sep 18, 20084

Timeline

  1. Jan 4, 2024New chief executive Maher Masoud becomes CEO13
  2. Jul 29, 2021New chief executive Douglas Doerfler becomes CEO14
  3. Jul 2021Went public Listed on NASDAQ1
  4. Mar 2016Went public Listed on London Stock Exchange1
  5. Jul 31, 1998Founded MaxCyte (United States) is founded3

Filings

277 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 51 major events, 135 insider forms, 33 large holders, 37 other. The latest 20:

  1. Oct 15, 2026SCHEDULE 13D EDGAR
  2. Oct 14, 20268-K EDGAR
  3. Aug 13, 202610-Q EDGAR
  4. Aug 12, 20268-K EDGAR
  5. Aug 4, 2026SCHEDULE 13D EDGAR
  6. Jul 29, 2026SCHEDULE 13G/A EDGAR
  7. Jun 22, 20264 EDGAR
  8. Jun 22, 20264 EDGAR
  9. Jun 22, 20264 EDGAR
  10. Jun 22, 20264 EDGAR
  11. Jun 22, 20264 EDGAR
  12. Jun 22, 20264 EDGAR
  13. Jun 22, 20264 EDGAR
  14. Jun 22, 20264 EDGAR
  15. Jun 17, 20268-K EDGAR
  16. Jun 16, 20268-K EDGAR
  17. May 14, 2026SCHEDULE 13D EDGAR
  18. May 13, 202610-Q EDGAR
  19. May 12, 20268-K EDGAR
  20. Apr 29, 2026ARS EDGAR

The 277 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

105 open-market trades by officers, directors and large owners since October 2021: 9 buys and 96 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Mar 17, 2026Swirsky Douglas JCHIEF FINANCIAL OFFICERSale10,142$0.82$8.3KForm 4
Aug 13, 2025Swirsky Douglas JCHIEF FINANCIAL OFFICERBuy50,000$1.29$64.5KForm 4
Aug 13, 2025Masoud MaherPresident and CEOBuy75,000$1.37$102.8KForm 4
Aug 13, 2025Erck Stanley CDirectorBuy100,000$1.37$137.0KForm 4
Aug 13, 2025DOUGLAS RICHARDDirectorBuy80,000$1.39$111.2KForm 4
Aug 13, 2025Brooke William WDirectorBuy50,000$1.29$64.5KForm 4
Jun 25, 2025Hemrajani RekhaDirectorSale10,684$2.09$22.3KForm 4
Mar 18, 2025Soleymannezhad AliChief Commercial OfficerSale1,211$3.18$3.9KForm 4
Mar 18, 2025Sandoval David I.GENERAL COUNSELSale353$3.18$1.1KForm 4
Mar 18, 2025Swirsky Douglas JCHIEF FINANCIAL OFFICERSale6,939$3.18$22.1KForm 4
Jan 27, 2025Johnston John JosephDirectorSale3,000$4.65$13.9KForm 4
Jan 13, 2025Sandoval David I.GENERAL COUNSELSale4,466$4.54$20.3KForm 4
Dec 26, 2024Johnston John JosephDirectorSale3,000$4.01$12.0KForm 4
Dec 9, 2024Johnston John JosephDirectorSale2,495$3.79$9.5KForm 4
Dec 6, 2024Johnston John JosephDirectorSale505$3.70$1.9KForm 4
Nov 1, 2024Erck Stanley CDirectorSale47,689$3.72$177.4KForm 4
Oct 28, 2024Johnston John JosephDirectorSale3,000$3.72$11.2KForm 4
Oct 2, 2024Erck Stanley CDirectorSale21,607$3.71$80.2KForm 4
Oct 1, 2024Erck Stanley CDirectorSale26,082$3.78$98.6KForm 4
Sep 26, 2024Johnston John JosephDirectorSale3,000$3.82$11.5KForm 4

All 105 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Capricorn Fund Managers Ltd8,200,000$10.1M0.8%No change
Vitruvian Partners LLP5,043,356$6.2M3.1%No change
Vanguard Capital Management LLC4,031,284$5.0M0.0%+49,468
Morgan Stanley3,694,049$4.5M0.0%+5,918
Mudita Advisors LLP3,370,689$4.1M0.9%No change
BlackRock, Inc.3,060,960$3.8M0.0%−5,737,513
Brooklands Fund Management Ltd2,848,083$3.7M2.9%+658,063
BNP PARIBAS ASSET MANAGEMENT Holding S.A.2,773,554$3.4M0.0%No change
Cadian Capital Management, LP2,201,166$2.7M0.2%+478,224
Peapod Lane Capital LLC2,125,752$2.6M1.8%+793,559
Renaissance Technologies LLC1,910,800$2.4M0.0%−82,400
Aqr Capital Management LLC1,882,776$2.3M0.0%+661,594
Jane Street Group, LLC1,563,003$1.9M0.0%+1,542,434
Two Sigma Investments, LP1,462,941$1.8M0.0%+854,779
Geode Capital Management, LLC1,326,914$1.6M0.0%−1,035,758
RBF Capital, LLC1,322,443$1.6M0.1%New
Goldman Sachs Group Inc1,241,943$1.5M0.0%+82,924
Millennium Management LLC1,204,921$1.5M0.0%+1,161,862
Nano Cap New Millennium Growth Fund L P1,200,000$1.5M1.1%+200,000
Marshall Wace, Llp1,014,778$1.2M0.0%+915,866
Willis Investment Counsel862,758$1.1M0.1%No change
Citadel Advisors LLC856,318$1.1M0.0%+523,230
Stonepine Capital Management, LLC751,606$924.5K0.7%−253,067
Vanguard Fiduciary Trust Co653,203$803.4K0.0%+9,997
George Kaiser Family Foundation627,536$771.9K0.1%+145,733

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42